Rani Therapeutics Holdings (RANI) Profit After Tax (2020 - 2026)

Rani Therapeutics Holdings' Profit After Tax history runs 7 years deep, the most recent figure standing at -$7.0 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 44.79% year-over-year to -$7.0 million in Q1 2026; TTM through Mar 2026 was -$45.3 million, a 6.9% increase from a year earlier, with the FY2025 full-year figure at -$40.9 million, up 27.63% from the prior year.
• Profit After Tax climbed to -$7.0 million in Q1 2026 per RANI's latest filing, from -$21.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at $19.9 million in Q4 2023 and bottomed at -$41.5 million in Q4 2022.
• The 5-year median for Profit After Tax is -$13.8 million (2022), against an average of -$13.0 million.
• Across the five-year window, Profit After Tax tumbled 212.23% in 2022 and jumped 147.8% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$41.5 million in 2022, then soared by 147.8% to $19.9 million in 2023, then slumped by 179.17% to -$15.7 million in 2024, then slumped by 37.27% to -$21.6 million in 2025, then jumped by 67.41% to -$7.0 million in 2026.
• Per Business Quant, the three latest RANI Profit After Tax figures stand at -$7.0 million (Q1 2026), -$21.6 million (Q4 2025), and -$5.4 million (Q3 2025).